Revisiting AMPA receptors as an antiepileptic drug target

Epilepsy Currents

Volumn 11, Issue 2, 2011, Pages 56-63

  Rogawski, Michael A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; 2 AMINO 5 PHOSPHONOVALERIC ACID; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; DIZOCILPINE; GLUTAMIC ACID; IONOTROPIC RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PERAMPANEL; PHENCYCLIDINE; TALAMPANEL;

AMINO ACID SEQUENCE; ATAXIA; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; HUMAN; MEDICAL RESEARCH; NONHUMAN; PROTEIN DOMAIN; PROTEIN LOCALIZATION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SEIZURE; SOMNOLENCE;

EID: 84856685605     PISSN: 15357597     EISSN: 15357511     Source Type: Journal    
DOI: 10.5698/1535-7511-11.2.56     Document Type: Review

References (73)

1. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R. Glutamate receptorion channels: structure, regulation, and function. Pharmacol Rev 2010;62:405-496.
2. Megías M, Emri Z, Freund TF, Gulyás AI. Total number and distributionof inhibitory and excitatory synapses on hippocampal CA1 pyramidal cells. Neuroscience 2001;102:527-540.
3. Laezza F, Dingledine R. Induction and expression rules of synaptic plasticity in hippocampal interneurons. Neuropharmacology 2010;60:720-729.
4. Hollmann M, O'Shea-Greenfield A, Rogers SW, Heinemann S. Cloningby functional expression of a member of the glutamate receptor family. Nature 1989;342(6250):643-648.
5. Lodge D. The history of the pharmacology and cloning of ionotropicglutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology 2009;56:6-21.
6. Mayer ML. Glutamate receptors at atomic resolution. Nature2006;440(7083):456-462.
7. Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetryand mechanism of an AMPA-subtype glutamate receptor. Nature 2009;462(7274):745-756.
8. Szénási G, Vegh M, Szabo G, Kertesz S, Kapus G, Albert M, Greff Z, LingI, Barkoczy J, Simig G, Spedding M, Harsing LG Jr. 2,3-benzodiazepinetype AMPA receptor antagonists and their neuroprotective effects. Neurochem Int 2008;52:166-183.
9. Balannik V, Menniti FS, Paternain AV, Lerma J, Stern-Bach Y. Molecularmechanism of AMPA receptor noncompetitive antagonism. Neuron 2005;48:279-288.
10. Wenthold RJ, Petralia RS, Blahos J II, Niedzielski AS. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci 1996;16:1982-1989.
11. Isaac JT, Ashby M, McBain CJ. The role of the GluR2 subunit in AMPAreceptor function and synaptic plasticity. Neuron 2007;54:859-871.
12. Díaz E. Regulation of AMPA receptors by transmembrane accessoryproteins. Eur J Neurosci 2010;32:261-268.
13. Cokic B, Stein V. Stargazin modulates AMPA receptor antagonism.Neuropharmacology 2008;54:1062-1070.
14. Collingridge GL, Isaac JT, Wang YT. Receptor trafficking and synapticplasticity. Nat Rev Neurosci 2004;5:952-962.
15. Kessels HW, Malinow R. Synaptic AMPA receptor plasticity and behavior.Neuron 2009;61:340-350.
16. Rogawski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Li H. GluR5 kainate receptors, seizures, and the amygdala. Ann NY Acad Sci 2003;985:150-162.
17. Jane DE, Lodge D, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology 2009;56:90-113.
18. Vincent P, Mulle C. Kainate receptors in epilepsy and excitotoxicity.Neuroscience 2009;158:309-323.
19. Fritsch B, Gasior M, Kaminski, Rogawski MA. Role of kainate receptorsubunits in seizure induction as assessed with kainate receptor knockout mice, Epilepsia 2006;47 (Suppl. 4): 305.
20. Takagaki G. The dawn of excitatory amino acid research in Japan. The pioneering work by Professor Takashi Hayashi. Neurochem Int 1996;29:225-229
21. Curtis DR, Phillis JW, Watkins JC. Chemical excitation of spinal neurones. Nature 1959;183(4661):611-612.
22. Watkins JC, Jane DE. The glutamate story. Br J Pharmacol 2006;147 Suppl 1:S100-S108.
23. Watkins JC. Some chemical highlights in the development ofexcitatory amino acid pharmacology. Can J Physiol Pharmacol 1991;69:1064-1075.
24. Krogsgaard-Larsen P, Honoré T, Hansen JJ, Curtis DR, Lodge D. New class of glutamate agonist structurally related to ibotenic acid. Nature 1980;284(5751):64-66.
25. Evans RH, Francis AA, Jones AW, Smith DA, Watkins JC. The effects of a series of ω-phosphonic α-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br J Pharmacol 1982;75:65-75.
26. 3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res 1986;382:169-173.
27. Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 1993;14:325-331.
28. Honoré T, Davies SN, Drejer J, Fletcher EJ, Jacobsen P, Lodge D, Nielsen FE. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 1988;241(4866):701-703.
29. Sheardown MJ, Nielsen EØ, Hansen AJ, Jacobsen P, Honoré T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant or cerebral ischemia. Science 1990;247(4942):571-574.
30. Donevan SD, Rogawski MA. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 1993;10:51-59.
31. Tarnawa I, Vizi ES. 2,3-Benzodiazepine AMPA antagonists. Rest Neurol Neurosci 1998;13:41-75.
32. Donevan SD, Yamaguchi S, Rogawski MA. Non-N-methyl-D-aspartatereceptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J Pharmacol Exp Ther 1994;271 :25-29.
33. Rogawski MA. Talampanel. In: Bialer M, Johannessen SI, KupferbergHJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 2007;73:1-52.
34. Lazzaro JT, Paternain AV, Lerma J, Chenard BL, Ewing FE, Huang J, Welch WM, Ganong AH, Menniti FS. Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 2002;42:143-153.
35. Swartz J, Laurenza A. Perampanel. In: Bialer M, Johannessen SI, LevyRH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92:89-124.
36. Rogawski MA. Excitatory amino acids and seizures. In: CNS Neurotransmitters and Neuromodulators, Volume 1: Glutamate. (Stone TW, ed.) Boca Raton: CRC Press, 1995:219-237.
37. Neuman R, Cherubini E, Ben-Ari Y. Epileptiform bursts elicited in CA3 hippocampal neurons by a variety of convulsants are not blocked by N-methyl-D-aspartate antagonists. Brain Res 1988;459:265-274.
38. Mody I, Lambert JD, Heinemann U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J Neurophysiol 1987;57:869-888.
39. Lee W-L, Hablitz JJ. Involvement of non-NMDA receptors in picrotoxin-induced epileptiform activity in the hippocampus. Neurosci Lett 1989;107:129-134.
40. Perreault P, Avoli M. Physiology and pharmacology of epileptiform activity induced by 4-aminopyridine in rat hippocampal slices. JNeurophysiol 1991;65:771-785.
41. Hwa GG, Avoli M. The involvement of excitatory amino acids in neocorticalepileptogenesis: NMDA and non-NMDA receptors. Exp Brain Res 1991;86:248-256.
42. Hwa GGC, Avoli M. Excitatory synaptic transmission mediated by NMDA and non-NMDA receptors in the superficial/middle layers of the epileptogenic human neocortex maintained in vitro. Neurosci Lett 1992;143:83-86.
43. Gean PW. The epileptiform activity induced by 4-aminopyridine in ratamygdala slices: antagonism by non-N-methyl-D-aspartate receptor antagonists. Brain Res 1990;530:251-256.
44. Barna B, Szász A, Világi I, Szente M. Anticonvulsive effect of AMPA receptor antagonist GYKI 52466 on 4-aminopyridine-induced cortical ictal activity in rat. Brain Res Bull 2000;51:241-248.
45. Sveinbjornsdottir S, Sander JW, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe D, Duncan JS. The excitatory amino acid antagonistD-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993;16:165-174.
46. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of theanticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and γ-aminobutyric acidA receptors. Ann Neurol 1994;35:229-234.
47. Rogawski MA. Epilepsy. In: Neurotherapeutics: Emerging Strategies (Pullan L, Patel J, eds.), Totowa, NJ: Humana Press, 1996:193-273.
48. Löscher W, Hönack D. Anticonvulsant and behavioral effects of twonovel competitive N-methyl-D-aspartic acid receptor antagonists,CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J Pharmacol Exp Ther1991;256:432-440.
49. Dziki M, Hönack D, Löscher W. Kindled rats are more sensitive thannon-kindled rats to the behavioural effects of combined treatment with MK-801 and valproate. Eur J Pharmacol 1992;222:273-278.
50. Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity ofAMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res 1993;15:179-184.
51. Löscher W, Hönack D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil. Br J Pharmacol 1994;113:1349-1357.
52. Tortorella A, Halonen T, Sahibzada N, Gale K. A crucial role of the a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype of glutamate receptors in piriform and perirhinal cortex for the initiation and propagation of limbic motor seizures. J Pharmacol Exp Ther 1997;280:1401-1405.
53. De Sarro G, Gitto R, Russo E, Ibbadu GF, Barreca ML, De Luca L, Chimirri A. AMPA receptor antagonists as potential anticonvulsant drugs. Curr Top Med Chem 2005;5:31-42.
54. Löscher W, Rundfeldt C, Hönack D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur J Neurosci 1993;5:1545-1550.
55. Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology 2001;40:28-35.
56. Pitkänen A, Mathiesen C, Rønn LC, Møller A, Nissinen J. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 2007;74:45-54.
57. Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia 2010;51:108-117.
58. B receptor antagonists and their interactionin rats with a genetic form of absence epilepsy. Eur J Pharmacol 2001;430:251-259.
59. Jakus R, Graf M, Ando RD, Balogh B, Gacsalyi I, Levay G, Kantor S,Bagdy G. Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res 2004;1008:236-244.
60. Hashizume Y, Hanada T, Ogasawara A, Ueno M, Nishizawa Y. Anticonvulsant activity of perampanel, a selective AMPA receptor antagonist,in rodent models of epileptic seizure. Poster P02.113 presented at the 60th Annual Meeting of the American Academy of Neurology, 2008.
61. Weiser T. AMPA receptor antagonists for the treatment of stroke. CurrDrug Targets CNS Neurol Disord 2005;4:153-159.
62. Katsumori H, Minabe Y, Osawa M, Ashby CR Jr. Acute effects of various GABA receptor agonists and glutamate antagonists on focal hippocampal seizures in freely moving rats elicited by low-frequency stimulation. Synapse 1998;28:103-109.
63. Rogawski MA. Low affinity channel blocking (uncompetitive) NMDAreceptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids 2000;19:133-149.
64. Perucca E. What is the promise of new antiepileptic drugs in statusepilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS- 1209, and topiramate. Epilepsia 2009;50 (Suppl 12):49-50.
65. Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, Bjerke J, Kiesler GM, Arroyo S. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002;58:1680-1682.
66. Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JW,Patsalos PN. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience inpatients with chronic intractable epilepsy. Epilepsia 2003;44:46-53.
67. Danielsson I, Wassermann EV, Rogawski MA. AMPA receptor blockade and human cortical excitability-an EEG study. Program No. 99.3 2003 Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2003. Online.
68. Templeton D. Pharmacokinetics of perampanel, a highly selectiveAMPA-type glutamate receptor antagonist. Epilepsia 2009;50 (Suppl 11): 98 (Abst 1.199).
69. Krauss G, Yang J, Biton V, Klapper J, Bar M, Ivan Rektor I. Determinationof maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics (PK) of perampanel, a selective AMPA receptor antagonist, as adjunctive therapy in subjects with refractory partial seizures. Epilepsia 2008;49 (Suppl 7):1-498 (Abst 1.106).
70. Squillacote D, Krauss G, Vaiciene-Magistris N, Kumar D. A phase II study evaluating the safety, tolerability and efficacy of perampanel, a selective AMPA receptor antagonist, in patients with refractory partial seizures. American Epilepsy Society 2010 Annual Meeting. Epilepsy Curr 2011;11 (Suppl 1): (Abst 1.280).
71. Krauss GL, Serratosa JM, Villanueva VE, Endziniene M, Hong Z, FrenchJ, Yang H, Squillacote D, Zhu J, Laurenza A. Efficacy and safety of perampanel, an AMPA receptor antagonist, as an adjunctive therapy in a Phase III study of patients with refractory partial-onset seizures. American Epilepsy Society 2010 Annual Meeting. Epilepsy Curr 2011;11 (Suppl 1): (Abst 2.38).
72. Weaver DF, Sankar R. Basic principles of medicinal chemistry. In: Epilepsy: A Comprehensive Textbook, 2nd ed (Engel Jr J, Pedley TA, eds.) Philadelphia: Lippincott Williams & Wilkins:2008;1447-1455.
73. Rogawski MA. Molecular targets versus models for new antiepilepticdrug discovery. Epilepsy Res 2006;68:22-28.